FOLLOW US

Eikon's Upsized $381M IPO

America February 5, 2026

Eikon’s Upsized $381M IPO Ignites Nasdaq Debut

Oncology-focused biopharmaceutical firm Eikon Therapeutics stepped onto the public stage Thursday, as Eikon’s Upsized $381M IPO powered its Nasdaq debut…

By Rachel Moore

Signup for the USA Herald
exclusive Newsletter